Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
According to MarketBeat, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average price target of $18.
Therefore, the recommendation is to avoid NeoGenomics, Inc. shares at these levels even as management has strung together a string of commendable quarterly results.
Source: https://seekingalpha.com/article/4605815-neogenomics-what-lies-ahead?source=feed_all_articles
Tower Research Capital LLC TRC increased its stake in shares of NeoGenomics by 165.6% in the 1st quarter.